Point of Care Diagnostics & Other Healthcare Industry Segment Reports by Kalorama Information
26 Mar 2012 • by Natalie Aster
Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations). This report provides essential marketing and technical commentary on POC testing in developing countries, detailing opportunities for test makers and reviews of products on the market and in development. Infectious diseases, primarily STDs, tuberculosis, malaria, HIV and hepatitis, are the number one public health problem worldwide, and increased world travel has introduced viruses, parasites and bacteria from emerging countries to the developed world. POC markets such as glucose are saturated and will not provide the growth opportunities that are expected from emerging infectious disease tests. These tests are expected to show double digit growth for the next five years, faster than traditional infectious disease tests at 5% or common POC areas such as glucose, pregnancy or drugs of abuse testing which will grow at 1?2%.
Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations). There is much discussion about emerging markets in in-vitro diagnostics, especially the BRIC nations of Brazil, Russia, India and China. Which companies have been successful in these markets and how have they accomplished it? What kind of realistic growth can marketers expect by selling products in these areas? This essential report addresses these questions and much more, providing a realistic look at the IVD market in these key emerging markets, which combined have a CAGR of 12% from 2009 to 2014. Visit our website for more details about this report, an essential tool for diagnostic companies looking for growth opportunities in emerging markets.
World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing). In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to looking at products currently on the market and in development, the report profiles key competitors and discusses trends important for understanding this much-discussed and highly active growth area of the diagnostic industry. A special focus of the report is the bustle of activity with collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs. This report profiles scores of such companies operating in this market and estimates and forecasts markets for personalized medicine technologies in a variety of categories.
China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets. China’s rapid economic development and the numerous steps of reform undertaken by the Chinese central government since 1997 have had clear and observable effects upon China’s total healthcare services market and its product markets for pharmaceuticals, medical devices, and in vitro diagnostics (IVD). This progress has been augmented by a Reform program in 2009, which includes increased funding to improve services. What are the workings of China's healthcare system? How much progress has been made towards the promised vision of the CPCC in 2008 to provide convenient and affordable access" to its people? What are the effects on foreign companies seeking to benefit from an increase in healthcare-related funding? Where are the best opportunities in China for marketers? Kalorama analyst Emil Salazar focuses on these questions and more in this must-read report.
More new market research reports by can be found at Kalorama Information page.
To order the report or ask for sample pages contact [email protected]